Samsung Biologics Co Ltd
KRX:207940
Net Margin
Samsung Biologics Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
70.9T KRW |
26%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.1T USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
154.1B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
142.3B USD |
16%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
39.8B CHF |
10%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.8B USD |
18%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
200.9B CNY |
27%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.4B USD |
9%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
24.6B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.9B EUR |
7%
|
|
| US |
|
Waters Corp
NYSE:WAT
|
21B USD |
22%
|
Samsung Biologics Co Ltd
Glance View
In the bustling world of biopharmaceuticals, Samsung Biologics Co Ltd has carved a niche as a formidable player, merging cutting-edge technology with industrial scale to drive its operations. Situated in Incheon, South Korea, the company emerged as a key subsidiary of Samsung Group, bringing with it the organizational prowess and strategic vision that hallmark the conglomerate. Established with the goal of reshaping the global landscape of biopharmaceutical manufacturing, Samsung Biologics offers a suite of contract development and manufacturing organization (CDMO) services. From early-stage development to large-scale production, the company supports clients through every step of a biologic's lifecycle, ensuring seamless transition from laboratory to patient. The blend of state-of-the-art facilities and advanced process technologies enables them to meet the growing demands for complex biopharmaceuticals efficiently. Samsung Biologics' revenue machine spins around its comprehensive service spectrum, which includes drug substance and product manufacturing and laboratory testing services. The contract-based model allows global pharma companies to outsource crucial parts of their development and manufacturing processes to Samsung Biologics, thus optimizing costs and timelines. By building strategic partnerships and continuously investing in expanding its manufacturing capacity, Samsung Biologics not only captures market share but also aligns itself with the burgeoning demand for biosimilars and other next-generation therapeutics. Furthermore, operating within a highly regulated and competitive industry, the company's focus on maintaining stringent quality standards and regulatory compliance cements its reputation as a trusted partner in the pharmaceutical sector.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Net Margin of 26.1%.
You don't have any saved screeners yet